Zostavax in Part D Limbo
This article was originally published in RPM Report
Executive Summary
Just a few months after the first Part D vaccine was approved by FDA, it's clear reimbursement will be a barrier to successful adoption by physicians-at least in the near term. This is a looming problem for all new vaccines that will be covered under Part D.